Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Prospective, observational, multicenter PETHEMA study finds median TTP of MRD+ patients 38 mos vs NR if undetectable (p<.001), median PFS inferior in MRD+ patients (30 vs 62 mos, p<.001); MRD+ associated with progression and/or death.”
Title: Real-world evidence of measurable residual disease assessment in multiple myeloma
Authors: Maria Teresa Cedena, Noemi Puig, Bruno Paiva, Jose Enrique de la Puerta Rueda, Albert Pérez-Montaña, María Casanova, Joaquin Breña Atienza, Antoni Garcia, Felipe de Arriba, Carmen Martínez-Chamorro, Maialen Sirvent, María-Jesús Blanchard, Rafael Alonso Fernández, Miguel-Angel Alvarez Rivas, Francisco-Javier Capote, Ricarda García-Sánchez, José Juan Pérez, Sr., Paula Rodriguez-Otero, Juan-Jose Lahuerta, Joaquín Martínez-López, Maria-Victoria Mateos, Jesús F. San-Miguel
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
